Aeglea BioTherapeutics Inc (AGLE) is a clinical-stage biotechnology company that develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate, pegzilarginase, is being developed for the treatment of Arginase 1 Deficiency (ARG1-D), a rare and devastating metabolic disease that can lead to severe intellectual disability, spasticity, and early mortality.
In addition to pegzilarginase, Aeglea is also developing other product candidates based on its proprietary human enzyme platform, including ACN00177, a new preclinical candidate for the treatment of homocystinuria, and AEB3103, a preclinical-stage product candidate for the treatment of Indoleamine 2,3-dioxygenase 1 (IDO1)-expressing solid tumors.
Aeglea's proprietary technology platform is designed to create human enzymes with enhanced properties and capabilities. By engineering the enzymes to have improved efficacy, safety, and pharmacokinetic properties, Aeglea aims to provide patients with better therapeutic outcomes and reduce the overall burden of rare genetic diseases and cancer.